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Abstract—These days, inhalation constitutes a promising administration route for many drugs.
However, this route exhibits unique limitations, and formulations aimed at pulmonary delivery should
include as few as possible additives in order to maintain lung functionality. The purpose of this
work was to investigate the safety of lactose and chitosan to the pulmonary tissue when delivered
by inhalation. The study was carried out with 18 Wistar rats divided in three groups receiving
distilled water, lactose or chitosan. A solution of each excipient was administered by inhalation at
a dose of 20 mg. The lungs were excised and processed to determine several biochemical parameters
used as toxicity biomarkers. Protein and carbonyl group content, lipid peroxidation, reduced
and oxidized glutathione (GSSG), myeloperoxidase (MPO), cooper/zinc and manganese superoxide
dismutase, catalase, glutathione S-transferase and glutathione peroxidase were determined. Results of
myeloperoxidase activity and glutathione disulfide lung concentrations showed a relevant decrease
for chitosan group compared to control: 4.67 ± 2.27 versus 15.10 ± 7.27 (P = 0.011) for
MPO and 0.89 ± 0.68 versus 2.02 ± 0.22 (P = 0.014) for GSSG. The other parameters did not
vary significantly among groups. Lactose and chitosan administered by inhalation failed to show
toxic effects to the pulmonary tissue. A protective effect against oxidative stress might even be
attributed to chitosan, since some biomarkers had values significantly lower than those observed in
the control group when this product was inhaled. Nevertheless, caution must be taken regarding
chemical composition and technological processes applied to incorporate these products during drug
formulation, in particular for dry powder inhalators.
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INTRODUCTION
Inhalation nowadays constitutes one of the most promising administration routes
for many drugs, such as those of biotechnological origin not suitable for oral
administration, and also for other drugs used for the treatment of specific diseases
associated with the lung. Pulmonary delivery has many advantages over other
routes, although it also exhibits unique limitations [1, 2]. Formulations aimed
at pulmonary delivery should include as few as possible additives in order to
maintain lung functionality and to avoid respiratory pattern modifications since
administration of substances by inhalation raises specific safety concerns. New
technological strategies for the drug to reach the proper part of the pulmonary tree
and to remain as a depot for a desired period of time are being investigated and
recently applied. Lactose and chitosan have been proposed as auxiliary substances
for inhalation formulations, the former widely used in the pharmaceutical industry
as excipient in preparations given also by other routes of administration [3–6].
Notwithstanding, the literature is devoid of comprehensive reviews of lactose safety
when aimed at pulmonary delivery and most available data come from studies
performed to assess the potential toxicity of formulations containing an active
drug in the presence of lactose instead of evaluating lactose per se. Most results
from these inhalation studies revealed no finding of toxicological significance
with lactose although some of them comprised cases of minimal peribronchiolar
lymphoid hyperplasia in the lungs and carina and also lymph node lymphocyte
depletion together with alveolar macrophage infiltration in the lungs [7]. However,
a causal relationship between lactose and these effects is yet to be disclosed.
Several human studies [8, 9] have also evaluated the pharmacological effects of anti-
asthmatic drugs when formulated as dry powder in presence and absence of lactose
but only one [10] examined the effect of lactose per se in subjects with asthma and
bronchial hyperresponsiveness. Results showed that large doses of lactose powder
(600 mg over 20 min) inhaled through this form had little bronchoconstrictor or
irritant effect on the airways of the asthmatic subjects. Regarding chitosan, this term
is used to describe a series of polymers with different molecular weights, viscosity
and degree of deacetylation [11]. Derived from a naturally occurring source, this
polymer has shown to be both biocompatible and biodegradable [12]. The oral
LD50 for mice, 16 g/kg, indicates a very low-toxicity potential for this product
[13]. It is an approved food additive that has been considered for pharmaceutical
formulation and drug delivery applications, in which attention has been focused on
its absorption-enhancing, controlled release and bioadhesive properties.
Recently, chitosan-based delivery systems have been proposed to increase the
bioavailability of drugs both at the nasal mucosa and in the lungs [14–16];
also these systems have been reported as efficient vehicles for pulmonary gene
delivery [17–19] and several other important applications are being investigated
[11, 16, 20, 21]. Nevertheless chitosan is not included in the FDA Inactive
Ingredient Guide and very sparse data on its pulmonary toxicity are available.
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Pharmaceutical excipients have a vital role in drug formulations; however, few
toxicological data are available for many well-known excipients as those mentioned
above [22].
Considering the aforementioned putative pro-inflammatory effects of inhaled
chitosan and lactose, it is of interest to evaluate the effect of inhalation of these
products on pulmonary neutrophil infiltration and putative neutrophil-mediated
oxidative stress. In fact, the generation of reactive oxygen species (ROS) from
stimulated neutrophils is thought to play an important role in host defence and
tissue damage, but may also lead to oxidative stress [23]. When neutrophils
become activated, they initiate a “respiratory burst” by consuming molecular
oxygen (O2), resulting in the formation of superoxide radical (O•2) via the action
of a plasma-membrane NADPH oxidase. O•−2 is important as the primary product
for the neutrophil-induced generation of ROS but is quickly converted to hydrogen
peroxide (H2O2) spontaneously or by the enzyme superoxide dismutase (SOD).
H2O2 is not an inherently reactive compound, but can be transformed into highly
reactive and deleterious products: (i) the interactions of H2O2 with O•−2 or with
trace levels of transition metals can lead to the formation of hydroxyl radicals
(HO•); (ii) MPO, a hydrogen peroxide oxidoreductase that is specifically found in
mammalian granulocytic leukocytes, including neutrophils, monocytes, basophils
and eosinophils, contributes considerably to the bactericidal capabilities of these
cells via formation of HOCl from H2O2 and chlorine ions. Although the responses
of neutrophils to different stimulating conditions and pathogens are generally
beneficial for host defence, they can be deleterious to the organism if these cells
are inappropriately activated, mainly through oxidative stress.
Oxidative stress at sub-cellular level is a complex issue not able to be defined
with a single parameter. There are no available standardized methods to evaluate
this state in humans yet but a series of biomarkers of oxidative stress have been
proposed to make an overall estimation. Among these biomarkers the following are
widely used: (i) thiobarbituric acid reactive substances (TBARS) as indicative of
lipid peroxidation (LPO) [24]; (ii) carbonyl groups content to evaluate the degree
of oxidative proteins modification [25]; (iii) antioxidant enzymes activities, includ-
ing glutathione peroxidase (GPx), catalase (CAT), glutathione S-transferase (GST)
and copper/zinc and manganese superoxide dismutase (Cu/Zn SOD and MnSOD,
respectively), which have been found to be inducible in different cells in response
to oxidative stress [26]; (iv) myeloperoxidase (MPO), located within the primary
azurophil granules of polymorphonuclear (PMN) leukocytes, whose activity indi-
rectly reflects PMN infiltration through the organs during the inflammatory reaction
[27].
The present study was aimed at evaluating the above biochemical parameters as
biomarkers of toxicological effects of lactose and chitosan per se on the respiratory
system when directly exposed to each product by inhalation route. This type of
information is not available yet despite a wide research on pulmonary delivery of
lactose- and chitosan-containing formulations.
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MATERIALS AND METHODS
Chemicals
α-Lactose monohydrate (β-D-Gal-(1 → 4)-α-D-Glc4-O-β-D-Galactopyranosyl-
α-D-glucose), chitosan (chitosan from crab shells  75% (deacetylated) (2-
amino-2-deoxy-(1 → 4)-β-D-glucopyranan, molecular mass 31 kDa), L-Glutamic
acid, 3,3′,5,5′-Tetramethylbenzidine (TMB), NADPH (β-nicotinamide adenine din-
ucleotide phosphate reduced), GSH (L-glutathione reduced), GSSG (L-glutathione
oxidized), 2-Vinylpyridine, DNPH-2,4-dinitrophenylhydrazine, GSH reductase
(Glutathione Reductase from bakers yeast), H2O2, sodium azide (NaN3), CDNB
(1-chloro-2,4-dinitrobenzene) and xanthine oxidase were all obtained from Sigma
(Germany). Saline solution (NaCl 0.9%) and sodium thiopental (0.5 g) were ob-
tained from B. Braun (Spain). Sodium hydroxide (NaOH), 2-thiobarbituric acid
(C4H4N2O2S) and trichloroacetic acid (Cl3CCOOH), ethylenedinitrotetracetic acid
disodium salt dihydrate (Na2EDTA) were obtained from Merck (Germany).
Experimental protocol
18 Wistar male rats from Charles River (Spain) with a mean body weight of
308.17 ± 17.64 g were included in the study. Twelve hours prior the experiment,
animals were isolated in cages and allowed access to tap water ad libitum. Housing
and experimental treatment of animals were in accordance with the corresponding
Guide from the Institute for Laboratory Animal Research (ILAR 1996). The
experiments complied with the current laws of Portugal and Spain and adhere to the
“Principles of Laboratory Animal Care”. Animals were randomly distributed into
the following groups of 6 rats each: (i) control group, exposed to distilled water;
(ii) lactose group, exposed to 1% w/w lactose in distilled water and (iii) chitosan
group, exposed to 1% (w/w) chitosan in 0.1 M glutamic acid adjusted to pH 7.4
with 10 M NaOH.
Pulmonary exposure
After weighing, the animals were anesthesized with sodium thiopental (80 mg/kg,
intraperitoneal route). Then tracheotomy and tracheal cannulation were performed
with animals in the decubito supino position and immediately the cannula was
connected to a mechanical ventilation system (7025 Rodent Ventilator, Ugo Basile,
Italy) set at 60 respirations per min and 2 ml of tidal volume. 1000 IU sodium
heparin was injected by i.p. route to avoid clotting. A stabilization period of 5 min
was allowed prior starting inhalation. Water, lactose or chitosan solution (according
to rat group) were nebulized with aid of a nebulizer equipment (Ultrasonic Aerosol
Generator 700700-UV TSE system) connected to the artificial ventilation system
in such a way that the nebulized product came to the lungs through the cannula
for 40 min (total amount of excipient 20 mg). After this nebulization period the
nebulizer was disconnected and the animals were kept on mechanical ventilation
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until the end of experiment. In situ organ perfusion through the portal vein
was performed for 3 min with cold 0.9% saline solution at a perfusion rate of
10 ml/min (Minipuls® Gilson 3 pump) in order to clean the tissues from blood.
Simultaneously to the perfusion initiation, a cut at the abdominal aorta artery
was done to avoid overpressure. Then the thoracic cavity was open, the lungs
removed, weighed and processed as follows: the left lung lobe was dissected,
and homogenized (Ultra-Turrax® Homogenizer) in a cold aqueous solution of
5% (w/w) HClO4 at a proportion of 1 g tissue/4 ml solution. Aliquots of the
resulting supernatants were immediately used for evaluating the degree of LPO
through the quantification of TBARS. The remaining supernatants were stored
(−80◦C) for posterior quantification of GSH and GSSG. The pellet was used
for the quantification of protein carbonyl groups. The rest of lung tissue was
homogenized (Ultra-Turrax® Homogenizer) in a cold mixture of phosphate buffer
((KH2PO4 + Na2HPO4 · H2O) 50 mM, pH 7.4) and 0.1% (v/v) Triton X-100, 1 g
tissue/4 ml mixture. An aliquot for protein levels quantification was taken before
centrifugation (3000 × g, 4◦C, for 10 min). Aliquots of the resulting supernatants
were stored (−80◦C) for posterior quantification of antioxidant enzyme activities.
Protein quantification
Protein quantification was performed according to the method of Lowry et al. [28],
using bovine serum albumin as standard.
Measurement of oxidative stress biomarkers
Lipid peroxidation (LPO) was evaluated by the thiobarbituric acid-reactive sub-
stances (TBARS) assay [29]. Results are expressed as nanomol malondialde-
hyde (MDA) equivalents/mg protein using an extinction coefficient (ε) of 1.56 ×
105 M−1 cm−1.
Protein carbonyl groups (ketones and aldehydes) were determined according to
Levine et al. [30]. Results are expressed as nanomol DNPH incorporated/mg
protein (ε = 2.2 × 104 M−1 cm−1).
Mieloperoxidase (MPO) activity was measured according to the method followed
by Suzuki et al. [31] and Andrews et al. [32] with slight modifications as reported
by Dinis-Oliveira et al. [33]. Results are expressed as enzyme activity in U/g
protein.
Glutathione and glutathione disulfide (GSH and GSSG) concentrations were
determined by the 5,5′-dithiobis-2-nitrobenzoic acid-GSSG reductase recycling
assay previously described [34]. Results are expressed as nanomol GSH or
GSSG/mg protein.
Copper/zinc superoxide dismutase (CuZnSOD) and manganese superoxide dis-
mutase (MnSOD) were assayed using the method of Flohé and Otting [35] with
modifications set by Dinis-Oliveira et al. [36]. Results are expressed as enzyme
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activity in U/mg protein. 1 U of SOD activity is defined as the amount of enzyme
required to inhibit the rate of nitrotetrazolium blue (NTB) reduction by 50%.
Catalase activity (CAT) was measured according to the method of Aebi [37].
Results were expressed in U/mg protein (ε = 39.4 M−1 cm−1).
Glutathione peroxidase (GPx) activity was measured according to the method
of Flohé [38]. Results were expressed as enzyme activity in U/mg protein (ε =
6.22 mM−1 cm−1). 1 U of GPx represents 1 mmol NADPH oxidized/min per mg
protein.
Gutathione S-transferase (GST) activity was determined according to Warholm et
al. [39]. Results are expressed as enzyme activity in U/mg protein (1 U enzyme
activity is defined as the amount required to catalyse the synthesis of 1 µmol of
S-2,4-dinitrophenylgutathione per min at 30◦C).
Statistical analysis
Results are expressed as means ± SEM. Comparison of results from control and
excipient groups was performed by application of the non-parametric Kruskal–
Wallis test [40]. Statistical significance was established at the standard probability
value (P < 0.05).
RESULTS
Protein, LPO and carbonyl group quantification, as well as the activity of different
antioxidant enzymes used as inflammatory and tissue stress biomarkers were
determined in the lung of rats exposed to lactose or chitosan by inhalation route.
Figures 1 and 2 show the results obtained for oxidative stress-related biomarkers
assayed in control, lactose and chitosan groups. The most important finding was
obtained for MPO activity (U/g protein) and GSSG lung concentrations (nmol/mg
protein) that showed a relevant decrease for chitosan group compared to control:
4.67 ± 2.27 versus 15.10 ± 7.27 (P = 0.011) for MPO and 0.89 ± 0.68 versus
2.02 ± 0.22 (P = 0.014) for GSSG. For CAT (U/mg protein), a decrease was
found in the lactose group compared to control (18.22 ± 3.72 versus 13.25 ± 2.58;
P = 0.05).
Mean TBARS concentrations (nmol/mg protein) were 0.096 ± 0.018, 0.123 ±
0.075 and 0.098 ± 0.027 for control, lactose and chitosan groups, respectively,
with no statistical differences. Regarding carbonyl groups determination, animals
exposed to distilled water, lactose or chitosan showed a similar behaviour with mean
values of 4.56 ± 1.15, 4.33 ± 0.83 and 3.51 ± 1.16, respectively.
For GST and GPx activities (U/mg protein) mean values of 7.19 ± 0.89 (control),
5.88 ± 0.92 (lactose) and 6.80 ± 1.36 (chitosan) for the former and 82.94 ± 29.60
(control), 83.73 ± 30.45 (lactose) and 84.25 ± 10.08 (chitosan) for the latter were
obtained, with no statistical significant differences in any case.
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Figure 1. MPO lung activity (U/g protein), GSSG (nmol/mg protein), CAT (U/mg protein), lipid
peroxidation (nmol MDA/mg protein) and carbonyl group content (nmol/mg protein) in control,
lactose and chitosan groups. Values are given as means ± SEM (n = 6). P > 0.05, *P < 0.05,
**P < 0.01.
Results of GSH lung concentrations (nmol/mg protein) and the activities of
ZnCuSOD and MnSOD (U/mg protein) did not show statistical significance be-
tween groups showing the following mean values: 25.52 ± 7.11 (control), 29.02 ±
7.88 (lactose) and 31.61 ± 9.38 (chitosan) for GSH; 0.51 ± 0.18 (control), 0.41 ±
0.14 (lactose) and 0.31±0.0733 (chitosan) for ZnCuSOD and 0.0464±0.012 (con-
trol), 0.0589 ± 0.0302 (lactose) and 0.0456 ± 0.0065 (chitosan) for MnSOD.
DISCUSSION
According to our results lactose does not affect the pulmonary system of the rat
when administered at a dose of 20 mg by inhalation route since all the biomarkers
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Figure 2. GST (U/mg protein), GPX lung activity (U/mg protein), concentration of GSHGred
(nmol/mg protein) and activities of ZnCuSOD and MnSOD (U/mg protein) in control, lactose and
chitosan groups. Values are given as means ± SEM (n = 6). P > 0.05 for these markers.
assayed showed no statistically significant difference with respect to the control
group, although CAT activity showed a slight decrease in animals receiving lactose.
In lungs, catalase is localized in peroxisomes and in the cytoplasm of alveolar type II
pneumocytes and macrophages, a reduction of this enzyme being likely related to a
lower neutrophil recruitment. Catalase activity seems to be induced by hyperoxia,
oxidants and cytokines [41], which is the opposite of the results observed in the
present study that are in agreement with previous data on biocompatibility and
safety of lactose when used for pulmonary administration [7–10]. Considering that
the high doses used in the present study failed to produce toxicological effects on
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the lung tissue, these results confirm the behaviour of lactose per se as an inactive
ingredient for pulmonary delivery, under the present experimental conditions.
The results obtained with chitosan provided some significant changes when
compared to control group, although also not indicative of toxic effects. Differences
were observed for GSSG levels and MPO activity, which decreased significantly to
values representing 44% and 31% of control values, respectively, while a tendency
for a decrease in catalase activity was also observed. MPO and catalase results may
be explained by a lower recruitment of neutrophils, as explained above for lactose.
The reduction in GSSG concentration in the lung is also an interesting effect since it
derives from the antioxidant activity of GSH. GSH is present in high concentrations
in lung epithelial lining fluid [42] and has an important role in maintaining the
integrity of the airspace epithelium by playing a vital role in drug metabolism and
detoxification, in both type II alveolar cells in vitro and in lungs in vivo [43]. From
results obtained with GSSG and MPO an oxidative-stress-protective effect might
be attributed to chitosan, since a reduction of inflammatory cells lung infiltration
(assessed by quantification of MPO activity) implies less ROS production. More
studies on this topic would be interesting and necessary to confirm or contradict the
above statement.
Discrepancies are found between our results and those previously found by Huang
et al. [13]. These authors reported significant inflammatory response in the lung of
the rats at doses of 2–10 mg/kg of chitosan, while no toxicological effects were
detected in our study using a dose of 20 mg which corresponds to 60–70 mg/kg
for 308.17 ± 17.64 g of mean body weight. This may be due to differences in the
experimental protocol since the above authors administered chitosan microparticles
instead of the product dissolution. Despite the microparticles were reported to
be of spherical shape, with a size distribution from 1 to 4 µm, a high positive
charge and a density of 0.38 g/cm3 [44, 45], all properties that have shown to be
adequate for pulmonary therapy [46, 47], the inflammatory effects observed could
be attributed to their physical properties. In fact, their high cationic charge, which is
related to the degree of deacetylation, could be the cause of the toxicological effects
observed since cationic liposomes have also been reported to mediate pulmonary
inflammation due to surface charges [48–50]. Aggregation of microparticles in the
tracheal cannula while moving down to the lung or differences in molecular weight
of chitosan used might also be responsible for the negative effects reported.
CONCLUSIONS
The present study provides a methodological approach to evaluate the pulmonary
safety/toxicity of products assayed as pharmaceutical excipients for inhalation
delivery and reveals that lactose and chitosan per se do not produce oxidative
stress or inflammatory effects on the rat lungs after administration of doses as
high as 70 mg/kg by inhalation route. A protective effect against oxidative stress
might even be attributed to chitosan as far as some biomarkers reached values
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significantly lower than those observed in control group when this product was
inhaled. Nevertheless, high caution must be taken regarding chemical composition
(particularly for chitosan) and technological processes applied to these products
during drug formulation, in particular for dry powder inhalators.
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